Cochlear Poised for Medium-Term Growth on Nexa Launch, Jefferies Says

MT Newswires Live

Mar 17

Cochlear (ASX:COH) is expected to see solid operational performance and increased market share from its new Nexa cochlear implant system, despite short-term currency headwinds, Jefferies said in a Tuesday report.

Surgeons are increasingly adopting the Nucleus SmartNav tool with Nexa, giving the implant a competitive edge, while the company expects 11% cochlear implant volume growth in the second half of fiscal year 2026 and 13% in fiscal year 2027, driven by post-Nexa adoption, the report said.

Jefferies expects foreign exchange headwinds from rising Australian dollar to US dollar and Australian dollar to euro rates to reduce fiscal year 2026 underlying net profit by about AU$30 million, lowering it to around AU$404 million and causing earnings per share to decline 7% in fiscal year 2026 and 9% in fiscal year 2027.

The firm considers the company a high-quality, dominant global franchise with a proven track record, despite the short-term effects of currency fluctuations.

Jefferies maintained its buy rating on Cochlear and lowered the price target to AU$285 per share from AU$304 per share.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620102874"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620102874\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620102874?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 13:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620102874","market":"nz","top_or_hot":-1,"title":"Cochlear Poised for Medium-Term Growth on Nexa Launch, Jefferies Says","media":"MT Newswires Live","content":"<html><body><p> Cochlear (ASX:COH) is expected to see solid operational performance and increased market share from its new Nexa cochlear implant system, despite short-term currency headwinds, Jefferies said in a Tuesday report.</p><p>Surgeons are increasingly adopting the Nucleus SmartNav tool with Nexa, giving the implant a competitive edge, while the company expects 11% cochlear implant volume growth in the second half of fiscal year 2026 and 13% in fiscal year 2027, driven by post-Nexa adoption, the report said.</p><p>Jefferies expects foreign exchange headwinds from rising Australian dollar to US dollar and Australian dollar to euro rates to reduce fiscal year 2026 underlying net profit by about AU$30 million, lowering it to around AU$404 million and causing earnings per share to decline 7% in fiscal year 2026 and 9% in fiscal year 2027.</p><p>The firm considers the company a high-quality, dominant global franchise with a proven track record, despite the short-term effects of currency fluctuations.</p><p>Jefferies maintained its buy rating on Cochlear and lowered the price target to AU$285 per share from AU$304 per share.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cochlear Poised for Medium-Term Growth on Nexa Launch, Jefferies Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCochlear Poised for Medium-Term Growth on Nexa Launch, Jefferies Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-17 13:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Cochlear (ASX:COH) is expected to see solid operational performance and increased market share from its new Nexa cochlear implant system, despite short-term currency headwinds, Jefferies said in a Tuesday report.</p><p>Surgeons are increasingly adopting the Nucleus SmartNav tool with Nexa, giving the implant a competitive edge, while the company expects 11% cochlear implant volume growth in the second half of fiscal year 2026 and 13% in fiscal year 2027, driven by post-Nexa adoption, the report said.</p><p>Jefferies expects foreign exchange headwinds from rising Australian dollar to US dollar and Australian dollar to euro rates to reduce fiscal year 2026 underlying net profit by about AU$30 million, lowering it to around AU$404 million and causing earnings per share to decline 7% in fiscal year 2026 and 9% in fiscal year 2027.</p><p>The firm considers the company a high-quality, dominant global franchise with a proven track record, despite the short-term effects of currency fluctuations.</p><p>Jefferies maintained its buy rating on Cochlear and lowered the price target to AU$285 per share from AU$304 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620102874","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620102874","pubTimestamp":1773723720,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cochlear (ASX:COH) is expected to see solid operational performance and increased market share from its new Nexa cochlear implant system, despite short-term currency headwinds, Jefferies said in a Tue","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","COH.AU":"COCHLEAR LTD"},"translate_title":"杰富瑞(Jefferies)表示，科利耳(Cochlear)将因Nexa的推出而实现中期增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":1.5},"content_text":"Cochlear (ASX:COH) is expected to see solid operational performance and increased market share from its new Nexa cochlear implant system, despite short-term currency headwinds, Jefferies said in a Tuesday report.Surgeons are increasingly adopting the Nucleus SmartNav tool with Nexa, giving the implant a competitive edge, while the company expects 11% cochlear implant volume growth in the second half of fiscal year 2026 and 13% in fiscal year 2027, driven by post-Nexa adoption, the report said.Jefferies expects foreign exchange headwinds from rising Australian dollar to US dollar and Australian dollar to euro rates to reduce fiscal year 2026 underlying net profit by about AU$30 million, lowering it to around AU$404 million and causing earnings per share to decline 7% in fiscal year 2026 and 9% in fiscal year 2027.The firm considers the company a high-quality, dominant global franchise with a proven track record, despite the short-term effects of currency fluctuations.Jefferies maintained its buy rating on Cochlear and lowered the price target to AU$285 per share from AU$304 per share.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}